Rosiglitazone preserves islet β-cell function of adult-onset latent autoimmune diabetes in 3 years follow-up study

Diabetes Research and Clinical Practice

Volumn 83, Issue 1, 2009, Pages 54-60

  Yang, Zhifang ^a,b   Zhou, Zhiguang ^a   Li, Xia ^a   Huang, Gan ^a   Lin, Jian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Cell function; Rosiglitazone; The latent autoimmune diabetes in adults

Indexed keywords

C PEPTIDE; DIURETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ADULT; ARTICLE; CELL FUNCTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; EDEMA; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HUMAN; HYPOGLYCEMIA; LATENT AUTOIMMUNE DIABETES; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; FOLLOW-UP STUDIES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 57949092638     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.09.044     Document Type: Article

References (31)

1. Pozzilli P., and Mario U.-Di. Autoimmune diabetes not requiring insulin at diagnosis (latent autoimmune diabetes of adults): definition, characterization, and potential prevention. Diabetes Care 24 (2001) 1460-1467
2. Gianani R., Pugliese A., Bonner-Weir S., Shiffrin A.J., Soeldner J.S., Erlich H., et al. Prognostically significant heterogeneity of cytoplasmic islet cell antibodies in relatives of patients with type I diabetes. Diabetes 41 (1992) 347-353
3. Hagopian W.A., Karlsen A.E., Gottsäter A., Landin-Olsson M., Grubin C.E., Sundkvist G., et al. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type. J. Clin. Invest. 91 (1993) 368-374
4. Groop L., Tuomi T., Rowley M., Zimmet P., and Mackay I.R. Latent autoimmune diabetes in adults (LADA)-more than a name. Diabetologia 49 (2006) 1996-1998
5. Lohmann T., Kellner K., Verlohren H.J., Krug J., Steindorf J., Scherbaum W.A., et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 44 (2001) 1005-1010
6. Borg H., Gottsäter A., Landin-Olsson M., Fernlund P., and Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J. Clin. Endocrinol. Metab. 86 (2001) 3032-3038
7. Maruyama T., Shimada A., Kanatsuka A., Kasuga A., Takei I., Yokoyama J., et al. Multicenter prevention trials of slowly progressive type 1 diabetes with small dose of insulin (the Kyoto study): preliminary report. Ann. N. Y. Acad. Sci. 1005 (2003) 362-369
8. Behme M.T., Dupre J., Harris S.B., Hramiak I.M., and Mahon J.L. Insulin resistance in latent autoimmune diabetes of adulthood. Ann. N. Y. Acad. Sci. 1005 (2003) 374-377
9. Beales P.E., and Pozzilli P. Thiazolidinediones for the prevention of diabetes in the non-obese diabetic (NOD) mouse: implications for human type 1 diabetes. Diabetes Metab. Res. Rev. 18 (2002) 114-117
10. Zhou Z., Li X., Huang G., Peng J., Yang L., Yan X., et al. Rosiglitazone combined with insulin preserves islet beta cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab. Res. Rev. 21 (2005) 203-208
11. Li X., Zhou Z.G., Huang G., Yan X., Yang L., Chen X.Y., et al. Optimal cutoff point of glutamate decarboxylase antibody titers in differentiating two subtypes of adult-onset latent autoimmune diabetes. Ann. N. Y. Acad. Sci. 1037 (2004) 122-126
12. Wallace T.M., Levy J.C., and Matthews D.R. Use and abuse of HOMA modeling. Diabetes Care 27 (2004) 1487-1495
13. Beales P.E., Giorgini A., Annovazzi A., Signore A., Parlapiano C., and Pozzilli P. Metformin does not alter diabetes incidence in the NOD mouse. Horm. Metab. Res. 29 (1997) 261-263
14. J.P. Palmer, G.A. Fleming, C.J. Greenbaum, K.C. Herold, L.D. Jansa, H. Kolb, J.M. Lachin, K.S. Polonsky, P. Pozzilli, J.S. Skyler, M.W. Steffes, C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001, Diabetes 53 (2004) 250-264.
15. Shimada A., Imazu Y., Morinaga S., Funae O., Kasuga A., Atsumi Y., et al. T-cell insulitis found in anti-GAD65+ diabetes with residual β-cell function. Diabetes Care 22 (1999) 615-617
16. Fourlanos S., Dotta F., Greenbaum C.J., Palmer J.P., Rolandsson O., Colman P.G., et al. Latent autoimmune diabetes in adults (LADA) should be less latent. Diabetologia 48 (2005) 2206-2212
17. Leslie R.D., Williams R., and Pozzilli P. Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 91 (2006) 1654-1659
18. Kahn S.E., Haffner S.M., Heise M.A., Herman W.H., Holman R.R., Jones N.P., et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355 (2006) 2427-2443
19. Carlsson S., Midthjell K., Tesfamarian M.Y., and Grill V. Age, overweight and physical inactivity increase the risk of latent autoimmune diabetes in adults: results from the Nord-Trøndelag health study. Diabetologia 50 (2007) 55-58
20. Chiu H.K., Tsai E.C., Juneja R., Stoever J., Brooks-Worrell B., Goel A., et al. Equivalent insulin resistance in latent autoimmune diabetes in adults (LADA) and type 2 diabetic patients. Diabetes Res Clin Pract 77 (2007) 237-244
21. Carlsson A., Sundkvist G., Groop L., and Tuomi T. Insulin and glucagon secretion in patients with slowly progressing autoimmune diabetes (LADA). J Clin Endocrinol Metab 85 (2000) 76-80
22. Kamiya H., Zhang W., Ekberg K., Wahren J., and Sima A.A. C-Peptide reverses nociceptive neuropathy in type 1 diabetes. Diabetes 55 (2006) 3581-3587
23. Rebsomen L., Pitel S., Boubred F., Buffat C., Feuerstein J.M., Raccah D., et al. C-peptide replacement improves weight gain and renal function in diabetic rats. Diabetes Metab 32 (2006) 223-228
24. Yang X.Y., Wang L.H., Chen T., Hodge D.R., Resau J.H., DaSilva L., et al. Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem 275 (2000) 4541-4544
25. Wang P., Anderson P.O., Chen S., Paulsson K.M., Sjögren H.O., and Li S. Inhibition of the transcription factors AP-1 and NF-kappaB in CD4 T cells by peroxisome proliferator-activated receptor gamma ligands. Int Immunopharmacol 1 (2001) 803-812
26. + T-cells in type 1 diabetes. Diabetes 54 (2005) 1407-1414
27. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., and Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54 (2005) 92-99
28. Yang Z., Zhou Z., Huang G., Ling H., Yan X., Peng J., et al. The CD4(+) regulatory T-cells is decreased in adults with latent autoimmune diabetes. Diabetes Res Clin Pract 76 (2007) 126-131
29. Wohlfert E.A., Nichols F.C., Nevius E., and Clark R.B. Peroxisome proliferator-activated receptor gamma (PPARgamma) and immunoregulation: enhancement of regulatory T cells through PPARgamma-dependent and -independent mechanisms. J Immunol 178 (2007) 4129-4135
30. + T cell-mediated protection against colitis. J Immunol 178 (2007) 2940-2949
31. + T-cells expressing Foxp3. Diabetes 54 (2005) 1040-1047